Sun Pharmaceutical Industries Ltd (SUN.NS)
24 Nov 2015
** Indian drug makers attract short positions in derivatives even after being oversold
** Says new disclosure of Halol being classified as official action initiated (OAI) flag increases the chances of a warning letter
** Sun Pharmaceutical Industries slumps 5.3 pct, Dr.Reddy's Laboratories down 1.7 pct and Lupin falls 1.6 pct
** Traders cite optimism tied to launch of Keveyis drug in the U.S. market by unit Taro Pharmaceutical Industries
MUMBAI Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.
MUMBAI, Sept 10 Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.
* Says USFDA approved supplemental new drug application for ximino extended-release capsules 45 mg, 90 mg and 135 mg Source text for Eikon: http://bit.ly/1hMr5DX Further company coverage:
** Cites integration with Ranbaxy, price hikes at unit Taro and improvement in US supplies as key reason for the upgrade
** Sun Pharmaceutical Industries gains 3.8 pct, heading for a fourth day of gains
MUMBAI Indian stocks marked their highest close in more than three months on Wednesday, driven by value-buying in beaten-down stocks, while the adoption of a select committee report on a key national tax bill in parliament also helped.